CSL Behring, a provider of biotherapeutics, is expanding in Russia with the opening of operations there. CSL Behring focuses on developing protein-based therapies for the treatment of bleeding disorders, immune deficiencies, inherited respiratory disease and hereditary angioedema, and for neurological disorders in certain markets. CSL Behring is a subsidiary of CSL Limited. The company currently has seven products registered in Russia.

In addition, CSL Behring is investigating opportunities to contribute to the development of the Russian pharmaceutical industry, and identify the best ways to partner with the Russian government. As an example, because the amount of human plasma that is currently collected in Russia is insufficient to meet the growing demand for protein-based medicines, the company said it may be possible to transfer CSL Behring's plasma collection technology to Russia, and initiate toll manufacturing in that country.

Source: CSL